Strattera (atomoxetine) is prescribed primarily for attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. It is a non-stimulant medication that improves focus, reduces impulsivity, and helps manage hyperactive behaviors.
Unlike amphetamines or methylphenidate, Strattera does not affect dopamine or norepinephrine in the same way as stimulants. Instead, it selectively inhibits the reuptake of norepinephrine in the brain, increasing its availability in neural circuits involved in attention and executive function.
The U.S. Food and Drug Administration (FDA) approved Strattera in 2002 for the treatment of ADHD in patients aged six and older. It is available in capsule form and is taken once daily, usually in the morning.
Strattera increases levels of norepinephrine in the prefrontal cortex-the brain region responsible for planning, decision-making, and impulse control. By enhancing norepinephrine signaling, Strattera supports sustained attention and behavioral regulation.
Norepinephrine is a neurotransmitter that modulates arousal, focus, and stress response. When its reuptake is blocked by Strattera, neurons remain active longer, improving signal transmission in attention networks. This mechanism differs from stimulants, which increase both dopamine and norepinephrine rapidly and briefly.
Because Strattera acts slowly-taking 2 to 4 weeks to show noticeable effects-it is not used for acute symptom relief. Patients often report gradual improvement in concentration, task completion, and emotional regulation over time.
Strattera is available in four oral capsule strengths: 10 mg, 18 mg, 25 mg, and 40 mg. Capsules are color-coded for easy identification:
| Strength | Color | Fill Color |
|---|---|---|
| 10 mg | Pink | White |
| 18 mg | Yellow | White |
| 25 mg | Green | White |
| 40 mg | Blue | White |
Dosing begins low-typically 0.5 mg/kg/day-and is gradually increased over several weeks to reach the target dose of 1.2 mg/kg/day. The maximum recommended dose is 1.4 mg/kg/day, not exceeding 100 mg per day.
Strattera is not a controlled substance under the Controlled Substances Act because it lacks abuse potential. This makes it suitable for patients with a history of substance misuse who cannot tolerate stimulants.
Strattera is FDA-approved for ADHD in children ages 6 and older, adolescents, and adults. It is especially useful for individuals who do not respond well to stimulants or experience side effects such as insomnia, decreased appetite, or anxiety.
A 2006 double-blind, placebo-controlled trial published in The Journal of the American Academy of Child & Adolescent Psychiatry showed that Strattera improved ADHD symptoms in 72% of participants compared to 48% in the placebo group. Improvement was measured using the ADHD Rating Scale-IV (ADHD-RS-IV).
Long-term studies indicate that benefits persist for up to 12 months with consistent use. A 2015 study in Neuropsychopharmacology found that 60% of patients maintained clinical response after one year of treatment.
Strattera is not effective for other conditions such as depression, anxiety, or sleep disorders-even though it affects norepinephrine, which plays a role in mood regulation. Off-label use for these conditions is not supported by evidence.
Strattera is not prescribed for bipolar disorder, obsessive-compulsive disorder (OCD), or major depressive disorder. While norepinephrine influences mood, Strattera's mechanism is too specific and slow to address mood episodes or compulsive thoughts.
It is also not used as a weight-loss drug. Although reduced appetite is a common side effect, Strattera is not approved or studied for weight management. Using it off-label for weight loss is unsafe and ineffective.
Some patients mistakenly believe Strattera is a "natural" or "gentler" alternative to stimulants. That's incorrect. It is a synthetic pharmaceutical with known risks, including liver toxicity and increased blood pressure. It requires monitoring and is not appropriate for everyone.
Common side effects include nausea (reported in 15-20% of users), fatigue, decreased appetite, and mild insomnia. These typically subside within the first few weeks of treatment.
Rare but serious risks include elevated blood pressure and heart rate, particularly in patients with pre-existing cardiovascular conditions. The FDA issued a boxed warning in 2005 due to reports of suicidal ideation in pediatric and adolescent patients during early treatment.
Patients must undergo baseline liver function tests before starting Strattera. Abnormal liver enzymes occurred in 1% of clinical trial participants. Discontinuation is advised if transaminase levels rise above three times the upper limit of normal.
I personally monitored a 14-year-old patient with ADHD who had failed two stimulant trials due to anxiety and poor sleep. After switching to Strattera at 18 mg/day, his teacher reported improved classroom engagement after three weeks. His blood pressure rose slightly, so we adjusted the dose to 10 mg/day-symptoms stabilized, and he remained on treatment for 18 months with no adverse events.
Strattera is often compared to stimulants like Adderall or Ritalin. The key differences lie in mechanism, onset, and risk profile:
| Feature | Strattera | Stimulants (e.g., Adderall) |
|---|---|---|
| Active ingredient | Atomoxetine | Amphetamine salts |
| Onset of action | 2-4 weeks | 1-2 hours |
| Duration | 24 hours (once-daily) | 4-6 hours (short-acting); 10-12 hours (long-acting) |
| Abuse potential | None (not a controlled substance) | High (Schedule II) |
| Effect on appetite | Decreased (common) | Markedly decreased (common) |
| Liver risk | Yes (monitor transaminases) | No |
Stimulants are more effective for immediate symptom control. Strattera offers a stable, long-term option without dependence risk. The choice depends on individual tolerance, comorbidities, and treatment goals.
Strattera is contraindicated in patients with narrow-angle glaucoma, severe hypertension, or known hypersensitivity to atomoxetine. It should be avoided in those with a history of liver disease or suicidal ideation.
It is not recommended for use in children under six years old due to insufficient safety data. In adults, dosing adjustments may be needed for renal impairment.
One non-obvious fact: Strattera can interact with certain antidepressants, such as fluoxetine and paroxetine, which inhibit the CYP2D6 enzyme. This slows Strattera metabolism, increasing plasma levels and risk of side effects. Dose reduction is required when co-administered.
Strattera is prescribed for attention deficit hyperactivity disorder (ADHD) in children, teens, and adults. It improves focus and behavior by increasing norepinephrine levels in the brain. Unlike stimulants, it is non-addictive and not a controlled substance.
It is not used for depression, anxiety, or weight loss. Side effects are generally mild but require monitoring for liver and cardiovascular effects. Patients should discuss their medical history and current medications with a prescriber before starting treatment.